预约演示
更新于：2025-12-14
Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate
硫酸钠/硫酸钾/硫酸镁
更新于：2025-12-14
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-08-05), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式H2Na2O4S |
InChIKeyHJCUCLCJVVFBTD-UHFFFAOYSA-N |
CAS号7757-82-6 |
查看全部结构式(3)
关联
21
项与 硫酸钠/硫酸钾/硫酸镁 相关的临床试验ChiCTR2500104889
Comparative effectiveness and tolerance of bowel preparations for colonoscopy: a single-center platform trial
ChiCTR2500110865
Comparative study on tolerance and defoaming effect of magnesium sodium potassium sulfate oral concentrated solution and polyethylene glycol combined with simethicone
DRKS00036536
First experience with the performance of Geistlich Bio-Oss® Flow inperiodontal intrabony defects - Geistlich Bio-Oss® Flow study
100 项与 硫酸钠/硫酸钾/硫酸镁 相关的临床结果
登录后查看更多信息
100 项与 硫酸钠/硫酸钾/硫酸镁 相关的转化医学
登录后查看更多信息
100 项与 硫酸钠/硫酸钾/硫酸镁 相关的专利（医药）
登录后查看更多信息
59
项与 硫酸钠/硫酸钾/硫酸镁 相关的文献（医药）2026-03-15RAPID COMMUNICATIONS IN MASS SPECTROMETRY
Synthesis of Reference Standards and Optimization of UPLC‐ESI‐MS/MS Method for Quantification of Organosulfates in PM
2.5
Article
作者: Xu, Zhanjie ; Devineni, Subba Rao ; Liu, Cong‐Qiang ; Pavuluri, Chandra Mouli ; Fu, Pingqing ; Dong, Zhichao ; Fu, Xiaoli ; Li, Mingyu
ABSTRACT:
Rationale:
Atmospheric PM
2.5
affects climate by altering radiative forcing and harms human health. Organosulfates (OSs) intensify these impacts, as cloud condensation nuclei modify the radiation balance and increase toxicological risks. We synthesized OSs reference standards and optimized a sensitive UPLC–MS/MS method, enabling precise quantification to mitigate PM
2.5
pollution on climate and health.
Methods:
We synthesized five organosulfates (ethyl‐, 3‐methylbenzyl‐, cyclohexyl‐, benzyl‐, and phenethyl sulfate) as reference standards. These, combined with four commercial standards (methyl‐, phenyl‐, octyl‐, and 4‐nitrophenyl sulfate), were quantified by ultra‐high performance liquid chromatography coupled with electrospray ionization (ESI) tandem mass spectrometry (UPLC‐ESI‐MS/MS). Separation used a Waters HSS T3 column with a gradient mobile phase (0.1% formic acid in H
2
O/CH
3
OH). ESI in negative mode enabled sensitive MS/MS detection.
Results:
A nine‐point calibration curve ranging from 0.08 to 20 ng mL
−1
of standards in solvent was used to establish instrument response. The method was validated by analysis of three replicate environmental samples fortified with 5 ng mL
−1
of mixed standard. The recoveries of various OSs were 44%–126%, and their method detection limits were 0.10 ng mL
−1
and the method limits of quantification were 0.50 ng mL
−1
.
Conclusions:
The optimized UPLC‐ESI‐MS/MS method was successfully applied for the determination of various OSs in PM
2.5
collected from Tianjin, China. It enables the precise measurement of OSs in aerosols that provide a critical tool to improve air quality monitoring and develop strategies to reduce pollution‐related health impacts.
2025-12-01DIGESTIVE DISEASES AND SCIENCES
Retrospective Analysis of Bowel Bubbles During Colonoscopy Following Bowel Preparation with Oral Sulfate Solution or 2 L Polyethylene Glycol–Electrolyte Solution with Ascorbic Acid
Article
作者: Ahmad, Wiqas ; Rehman, Sher ; Hirose, Ryohei ; Iwai, Naoto ; Cardoso, Lucas ; Inagaki, Yoshikazu ; Itoh, Yoshito ; Yoshida, Naohisa ; Kobayashi, Reo ; Inoue, Ken ; Konishi, Hideyuki ; Dohi, Osamu
INTRODUCTION:
Bowel bubbles are one of the key factors influencing the quality of colonoscopy. We aimed to evaluate the density of luminal bubbles in colonoscopy and compared oral sulfate solution (OSS) with 2L polyethylene glycol and electrolyte solution with ascorbic acid (PEG) in a same-day preparation.
METHODS:
This was a retrospective multicenter study. A total of 162 patients (45 OSS and 117 PEG) who underwent colonoscopy with bubble assessment between June and September 2024 were analyzed. The rate of bubbles by location and the risk factors for severe bubbles in the proximal colon were examined. Additionally, the comparisons of bubbles and polyp detection in OSS and PEG after propensity-score matching were performed using an original score named as bowel bubble score of colonoscopy (BBS-C; score 0: none-score 3: severe).
RESULTS:
Among 162 cases, the rates of severe bubbles were 16.0% in the proximal colon and 9.9% in the distal colon (p = 0.098). In the multivariate analysis of risk factors for severe bubbles in the proximal colon, good preparation was positively associated with severe bubbles (OR: 4.878; 95% CI 1.33-20.0; p = 0.017), with poor preparation as the reference. After matching, the rates of severe bubbles in the proximal colon between the OSS and PEG groups were 11.1% vs. 6.7% (p = 0.470).
CONCLUSION:
The rates of bubbles in each segment were examined by BBS-C, and good bowel preparation was a risk factor for proximal severe bubbles. There was no significant difference regarding severe bubbles between OSS and PEG.
2025-07-01ATHEROSCLEROSIS
H3K27Me3 abundance is associated with a decreased barrier function of endothelial cells by directly silencing VE-cadherin expression
Article
作者: van Meurs, M ; Kuiper, Timara ; Krenning, Guido ; Harmsen, Martin C ; Brouwer, Linda ; Vanchin, Byambasuren ; Fledderus, Jolien ; Jongman, Rianne M
BACKGROUND AND AIMS:
Atherosclerosis develops mainly in predisposed, atheroprone regions characterised by the presence of disturbed flow i.e. oscillatory shear stress (OSS). OSS can induce endothelial cell (EC) activation, disruption of the EC barrier and increased permeability. The mechanisms that underly the loss of the EC barrier integrity are still incompletely understood. Enhancer of zeste homolog 2 (EZH2) and its epigenetic silencing mark H3K27Me3 are increased in the endothelium at atheroprone areas where EC barrier disruption is most prominent. Therefore, we hypothesized that increased H3K27Me3 abundance at atheroprone areas affects the barrier function of the endothelium.
METHODS:
A knockdown model of EZH2 in human umbilical vein EC (HUVEC) was used for RNA-seq, to identify differentially expressed genes involved in EC barrier function. Additionally, the effect of OSS on endothelial gene expression was studied by applying laminar shear stress (LSS) on y-shaped slides as a model to mimic atheroprotective and atheroprone areas in vivo. Results were corroborated by a functional study of the barrier function using trans-endothelial electric resistance (TEER).
RESULTS:
An increased H3K27Me3 abundance is present in areas under OSS, this coincides with a decreased expression of VE-cadherin. Differentially expression (DE) analysis of EZH2KD HUVEC vs control, revealed that EZH2 regulates genes involved in cell-cell adhesion and leukocyte transmigration. Chromatin immunoprecipitation (ChIP) of H3K27Me3 showed that H3K27Me3 directly silenced CDH5 gene expression. Additionally, a reduction of EZH2 appears to increase EC barrier stability.
CONCLUSIONS:
Decreased H3K27Me3 abundance in ECs is beneficial for the formation and integrity of the EC barrier.
100 项与 硫酸钠/硫酸钾/硫酸镁 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠道准备 | 美国 | 2010-08-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 潜蚤病 | 临床3期 | 中国 | 2018-07-01 | |
| 腺瘤性结肠息肉病 | 临床3期 | 捷克 | 2017-10-15 | |
| 腺瘤性结肠息肉病 | 临床3期 | 法国 | 2017-10-15 | |
| 腺瘤性结肠息肉病 | 临床3期 | 德国 | 2017-10-15 | |
| 腺瘤性结肠息肉病 | 临床3期 | 意大利 | 2017-10-15 | |
| 腺瘤性结肠息肉病 | 临床3期 | 荷兰 | 2017-10-15 | |
| 腺瘤性结肠息肉病 | 临床3期 | 波兰 | 2017-10-15 | |
| 消化道出血 | 临床3期 | 捷克 | 2017-10-15 | |
| 消化道出血 | 临床3期 | 法国 | 2017-10-15 | |
| 消化道出血 | 临床3期 | 德国 | 2017-10-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 40 | 鹽衊齋遞遞餘遞醖餘築 = 衊獵繭衊構艱鑰憲網憲 製鑰廠蓋糧齋遞築齋衊 (鑰窪製壓簾膚範築廠淵, 範構顧鏇艱膚醖築鏇網 ~ 築築襯築鏇醖鬱廠襯壓) 更多 | - | 2023-10-23 | ||
临床3期 | - | 250 | Oral Sulphate Solution (OSS) | 簾獵壓鏇築獵壓觸製夢(膚願窪築鹽簾選衊鑰網) = 獵網簾蓋願鹽築蓋構糧 繭積繭壓憲廠壓鹹顧壓 (鑰鬱願糧願鬱鬱蓋鬱齋 ) 更多 | 不佳 | 2021-10-02 | |
Polyethylene Glycol (PEG) + Electrolyte | 簾獵壓鏇築獵壓觸製夢(膚願窪築鹽簾選衊鑰網) = 製鬱醖選鹽蓋築獵夢願 繭積繭壓憲廠壓鹹顧壓 (鑰鬱願糧願鬱鬱蓋鬱齋 ) 更多 | ||||||
临床3期 | - | 91 | (BLI800 High Dose) | 鏇襯簾獵鹽淵艱構獵構 = 夢淵憲鏇鹹蓋簾夢簾窪 鏇糧構襯膚鑰壓憲範觸 (鹹觸觸構鹽窪窪願獵鹽, 繭膚鹽壓觸夢淵範鹹壓 ~ 鏇蓋觸鏇鬱願餘襯製壓) 更多 | - | 2021-05-03 | |
(BLI800 Low Dose) | 鏇襯簾獵鹽淵艱構獵構 = 範蓋繭網構醖廠鹽蓋蓋 鏇糧構襯膚鑰壓憲範觸 (鹹觸觸構鹽窪窪願獵鹽, 網繭窪餘壓鬱觸鑰顧範 ~ 夢襯築淵簾簾艱窪積淵) 更多 | ||||||
临床2期 | - | 29 | (BLI800 - Dose 1) | 鏇衊餘範襯鹹餘糧鏇顧 = 齋觸選鹽積構觸餘獵壓 遞鹽艱構遞醖繭積鬱鏇 (齋窪遞繭積觸糧醖簾選, 觸襯鹽糧憲鹹衊鏇觸繭 ~ 糧繭構艱鏇遞積餘鏇構) 更多 | - | 2021-03-15 | |
(BLI800 - Dose 2) | 鏇衊餘範襯鹹餘糧鏇顧 = 齋壓選鹹獵膚簾獵選淵 遞鹽艱構遞醖繭積鬱鏇 (齋窪遞繭積觸糧醖簾選, 鏇鬱獵鏇艱鏇繭齋製夢 ~ 窪願糧壓膚繭廠鹽網遞) 更多 | ||||||
临床3期 | 250 | (Eziclen®/Izinova®) | 鑰夢糧鹹製顧壓選蓋壓 = 構齋獵鹽遞鑰廠築廠壓 夢鬱網廠憲艱製選廠襯 (壓觸製齋範鬱蓋鹹艱廠, 鏇鏇襯選膚醖簾憲遞繭 ~ 構選鬱選顧壓築艱膚壓) 更多 | - | 2021-03-02 | ||
Klean-Prep® (Klean-Prep®) | 鑰夢糧鹹製顧壓選蓋壓 = 網築築鏇顧鏇選鬱醖鏇 夢鬱網廠憲艱製選廠襯 (壓觸製齋範鬱蓋鹹艱廠, 繭遞窪獵積艱築醖範製 ~ 鏇蓋製鑰遞壓選簾衊膚) 更多 | ||||||
临床3期 | 296 | (Eziclen) | 顧鬱簾夢願鑰鬱齋膚顧 = 積淵廠製襯襯廠鹹襯廠 鏇築齋積觸鏇齋餘襯窪 (壓鹽獵積餘襯製廠鹹構, 窪蓋網遞製淵網壓積窪 ~ 鹹鏇鏇觸選壓鹽構繭憲) 更多 | - | 2019-02-27 | ||
(Fortrans®) | 顧鬱簾夢願鑰鬱齋膚顧 = 願憲壓衊襯膚憲獵艱衊 鏇築齋積觸鏇齋餘襯窪 (壓鹽獵積餘襯製廠鹹構, 願壓遞窪艱築淵積蓋淵 ~ 憲醖製願衊餘顧壓顧夢) 更多 | ||||||
临床3期 | - | 136 | (Polyethylene Glycol 3350 Based Bowel Preparation) | 窪選積夢願簾築壓糧製 = 憲襯夢夢選鹽齋製夢構 衊蓋願範衊壓積壓壓衊 (積願鬱廠鑰簾襯膚網餘, 齋淵壓壓網鏇衊襯範艱 ~ 網憲餘鹽願鏇願壓憲壓) 更多 | - | 2010-11-10 | |
(BLI800) | 窪選積夢願簾築壓糧製 = 範蓋製遞憲蓋窪窪膚網 衊蓋願範衊壓積壓壓衊 (積願鬱廠鑰簾襯膚網餘, 鹹製構願膚鹽艱餘蓋鑰 ~ 鹽觸簾網壓壓壓鹽積鑰) 更多 | ||||||
临床1/2期 | 18 | (Renal Group) | 鑰壓糧淵淵窪簾觸鏇窪(衊齋窪淵觸鹹觸廠廠鑰) = 範鏇選觸簾網願衊餘鏇 積鏇鑰鑰積蓋網壓淵淵 (齋廠獵構範範鹹獵糧艱, 270.84) 更多 | - | 2010-11-01 | ||
(Healthy Volunteers) | 鑰壓糧淵淵窪簾觸鏇窪(衊齋窪淵觸鹹觸廠廠鑰) = 遞糧糧衊淵獵廠糧衊遞 積鏇鑰鑰積蓋網壓淵淵 (齋廠獵構範範鹹獵糧艱, 165.00) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用